Verywell Health on MSN1d
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant Depression
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
ScienceAlert on MSN6d
FDA-Approved Nasal Spray For Depression Is First Of Its Kind
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...
Boing Boing on MSN5d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
pharmaphorum6d
Axsome bounces back as FDA clears depression drug
That status goes to Johnson & Johnson's Spravato (esketamine), which was approved in March 2019 and is administered as a nasal spray twice a week for four weeks. However, it has a broader label as ...
pharmaphorum2d
Beckley builds case for its psychedelic depression therapy
According to Beckley, BPL-003 achieved an antidepressant response after a single intranasal dose – administered with psychological support – in 55% of patients assessed the day after dosing.
Reuters4d
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug
Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner Biogen's (BIIB.O), opens new tab Alzheimer's ...
Pharm Exec1d
New Spravato Indication Offers Greater Flexibility and Personalization for Patients with Treatment-Resistant Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...
Medical News Today3d
FDA-approved nasal spray for severe depression can lead to remission
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Managed Healthcare Executive6d
FDA and EMA Accepts Applications for New Nusinersen Regimen
An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...
FDA approves Spravato nasal spray as a standalone treatment for depression in adults
The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.
Pharm Exec3d
FDA Approves Supplemental Biologics License Application for Intravenous Maintenance Dosing of Leqembi in Alzheimer Disease
The FDA has approved a Supplemental Biologics License Application (sBLA) for intravenous maintenance dosing of Eisai and Biogen’s Leqembi (lecanemab) once every four weeks for patients with early ...